1422 / 1542
Prostate Cancer Level I (RCT) evidence:
EBRT +/- BT boost
Hoskin 2007 (UK)
Morris 2015 (Canada)
No. patients
218
398
Mean age yrs
68.9
68
Technique
HDR (8.5Gyx2)
LDR (115Gy)
Risk groups
Low 4%
Inter 42%
High 54%
Inter 31%
High 69%
Outcomes
At 7.1 yrs 31% reduction
in recurrence
50% reduction in PSA
recurrence
↑ late GU toxicity
Criticism
EBRT comparator only
55Gy/20
EBRT comparator 76Gy
but not IMRT/IGRT